SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-027987
Filing Date
2023-06-14
Accepted
2023-06-14 16:36:54
Documents
13
Period of Report
2023-06-13
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K inzy-20230613.htm   iXBRL 8-K 95795
2 EX-3.1 inzy-ex3_1.htm EX-3.1 255541
  Complete submission text file 0000950170-23-027987.txt   505761

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inzy-20230613_pre.xml EX-101.PRE 10615
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inzy-20230613.xsd EX-101.SCH 2466
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inzy-20230613_lab.xml EX-101.LAB 14449
7 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20230613_htm.xml XML 5061
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 231014624
SIC: 2834 Pharmaceutical Preparations